Ionic Low-Osmolar Versus Nonionic Iso-Osmolar Contrast Media to Obviate Worsening Nephropathy After Angioplasty in Chronic Renal Failure Patients. The ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study

JACC: Cardiovascular Interventions

Volumn 2, Issue 5, 2009, Pages 415-421

  Mehran, Roxana ^a,b   Nikolsky, Eugenia ^a,b   Kirtane, Ajay J ^a,b   Caixeta, Adriano ^a,b   Wong, S Chiu ^c   Teirstein, Paul S ^d   Downey, William E ^e   Batchelor, Wayne B ^f   Casterella, Peter J ^g   Kim, Young Hak ^a,b   Fahy, Martin ^a,b   Dangas, George D ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d SCRIPPS CLINIC   (United States)

^e MOSES CONE HEALTH SYSTEM   (United States)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g LDS HOSPITAL   (United States)

Author keywords

angiography; contrast media; renal insufficiency

Indexed keywords

ACETYLCYSTEINE; CREATININE; IODIXANOL; IONIC CONTRAST MEDIUM; IOXAGLIC ACID; NONIONIC CONTRAST MEDIUM; CONTRAST MEDIUM; IODOBENZOIC ACID DERIVATIVE;

AGED; ANGIOCARDIOGRAPHY; ANGIOPLASTY; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DETERIORATION; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; HYDRATION; INCIDENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; CHEMICALLY INDUCED; COMPLICATION; CORONARY ARTERY DISEASE; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; TIME;

AGED; ANGIOPLASTY, BALLOON; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IOXAGLIC ACID; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; RISK ASSESSMENT; TIME FACTORS; TRIIODOBENZOIC ACIDS;

EID: 65549151905     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.03.007     Document Type: Article

References (29)

1. Katzberg R.W., and Haller C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int Suppl (2006) S3-S7
2. Goldenberg I., and Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 172 (2005) 1461-1471
3. Mehran R., Aymong E.D., Nikolsky E., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44 (2004) 1393-1399
4. McCullough P.A., Wolyn R., Rocher L.L., Levin R.N., and O'Neill W.W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103 (1997) 368-375
5. Barrett B.J., and Parfrey P.S. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 354 (2006) 379-386
6. Mehran R., and Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl (2006) S11-S15
7. Taliercio C.P., Vlietstra R.E., Ilstrup D.M., et al. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol 17 (1991) 384-390
8. Lautin E.M., Freeman N.J., Schoenfeld A.H., et al. Radiocontrast-associated renal dysfunction: incidence and risk factors. Am J Roentgenol 157 (1991) 49-58
9. Davidson C., Stacul F., McCullough P.A., et al. Contrast medium use. Am J Cardiol 98 (2006) 42K-58K
10. Sharma S.K., and Kini A. Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials. Catheter Cardiovasc Interv 65 (2005) 386-393
11. McCullough P.A., Bertrand M.E., Brinker J.A., and Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 48 (2006) 692-699
12. Chalmers N., and Jackson R.W. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 72 (1999) 701-703
13. Aspelin P., Aubry P., Fransson S.G., Strasser R., Willenbrock R., and Berg K.J. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348 (2003) 491-499
14. Briguori C., Colombo A., Airoldi F., et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 68 (2005) 2250-2255
15. Jo S.H., Youn T.J., Koo B.K., et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol 48 (2006) 924-930
16. Barrett B.J., and Parfrey P.S. Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 331 (1994) 1449-1450
17. Grynne B.H., Nossen J.O., Bolstad B., and Borch K.W. Main results of the first comparative clinical studies on Visipaque. Acta Radiol Suppl 399 (1995) 265-270
18. Jakobsen J.A. Renal experience with Visipaque. Eur Radiol 6 Suppl 2 (1996) S16-S19
19. Sandler C.M. Contrast-agent-induced acute renal dysfunction-is iodixanol the answer?. N Engl J Med 348 (2003) 551-553
20. Aguejouf O., Doutremepuich F., Azougagh Oualane F., and Doutremepuich C. Thrombogenicity of ionic and nonionic contrast media tested in a laser induced rat thrombosis model. Thromb Res 77 (1995) 259-269
21. Fay W.P., and Parker A.C. Effects of radiographic contrast agents on thrombin formation and activity. Thromb Haemost 80 (1998) 266-272
22. Davidson C.J., Laskey W.K., Hermiller J.B., et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 101 (2000) 2172-2177
23. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
24. Solomon R., and Deray G. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl (2006) S51-S53
25. Solomon R.J., Natarajan M.K., Doucet S., et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 115 (2007) 3189-3196
26. Stone G.W., McCullough P.A., Tumlin J.A., et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290 (2003) 2284-2291
27. Briguori C., Airoldi F., D'Andrea D., et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115 (2007) 1211-1217
28. Tepel M., van der Giet M., Schwarzfeld C., Laufer U., Liermann D., and Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343 (2000) 180-184
29. Kshirsagar A.V., Poole C., Mottl A., et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 15 (2004) 761-769